123 related articles for article (PubMed ID: 24601730)
1. Exploring rates of abnormal pharmacogenetic findings in a pain practice.
Kirsh KL; Ehlenberger E; Huskey A; Strickland J; Egan City K; Passik SD
J Pain Palliat Care Pharmacother; 2014 Mar; 28(1):28-32. PubMed ID: 24601730
[TBL] [Abstract][Full Text] [Related]
2. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.
Swen JJ; van der Straaten T; Wessels JA; Bouvy ML; Vlassak EE; Assendelft WJ; Guchelaar HJ
Eur J Clin Pharmacol; 2012 Apr; 68(4):363-70. PubMed ID: 21984116
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing.
Hocum BT; White JR; Heck JW; Thirumaran RK; Moyer N; Newman R; Ashcraft K
Am J Health Syst Pharm; 2016 Jan; 73(2):61-7. PubMed ID: 26721535
[TBL] [Abstract][Full Text] [Related]
6. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV
Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.
Anderson GD
J Gend Specif Med; 2002; 5(1):25-33. PubMed ID: 11859684
[TBL] [Abstract][Full Text] [Related]
11. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
Jannetto PJ; Bratanow NC
Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
13. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
14. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
15. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
Müller DJ; Kekin I; Kao AC; Brandl EJ
Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
[TBL] [Abstract][Full Text] [Related]
16. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
Bousman CA; Jaksa P; Pantelis C
Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
18. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy.
Campbell NL; Skaar TC; Perkins AJ; Gao S; Li L; Khan BA; Boustani MA
Clin Interv Aging; 2015; 10():269-75. PubMed ID: 25609939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
